1241 related articles for article (PubMed ID: 8623922)
1. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.
Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD
Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922
[TBL] [Abstract][Full Text] [Related]
2. Apoptosis-related factors p53, Bcl2, and Bax in neuroendocrine lung tumors.
Brambilla E; Negoescu A; Gazzeri S; Lantuejoul S; Moro D; Brambilla C; Coll JL
Am J Pathol; 1996 Dec; 149(6):1941-52. PubMed ID: 8952529
[TBL] [Abstract][Full Text] [Related]
3. Bcl-2, p53, CD44, and CD44v6 isoform expression in neuroendocrine tumors of the lung.
Coppola D; Clarke M; Landreneau R; Weyant RJ; Cooper D; Yousem SA
Mod Pathol; 1996 May; 9(5):484-90. PubMed ID: 8733762
[TBL] [Abstract][Full Text] [Related]
4. Differential retinoblastoma and p16(INK4A) protein expression in neuroendocrine tumors of the lung.
Dosaka-Akita H; Cagle PT; Hiroumi H; Fujita M; Yamashita M; Sharma A; Kawakami Y; Benedict WF
Cancer; 2000 Feb; 88(3):550-6. PubMed ID: 10649246
[TBL] [Abstract][Full Text] [Related]
5. The significance of frequent and independent p53 and bcl-2 expression in large-cell neuroendocrine carcinomas of the lung.
Jiang SX; Kameya T; Shinada J; Yoshimura H
Mod Pathol; 1999 Apr; 12(4):362-9. PubMed ID: 10229500
[TBL] [Abstract][Full Text] [Related]
6. Primary large-cell neuroendocrine carcinoma of the parotid gland: immunohistochemical and molecular analysis of two cases.
Nagao T; Sugano I; Ishida Y; Tajima Y; Munakata S; Asoh A; Yamazaki K; Muto H; Konno A; Kondo Y; Nagao K
Mod Pathol; 2000 May; 13(5):554-61. PubMed ID: 10824928
[TBL] [Abstract][Full Text] [Related]
7. Thyroid transcription factor-1: immunohistochemical evaluation in pulmonary neuroendocrine tumors.
Folpe AL; Gown AM; Lamps LW; Garcia R; Dail DH; Zarbo RJ; Schmidt RA
Mod Pathol; 1999 Jan; 12(1):5-8. PubMed ID: 9950155
[TBL] [Abstract][Full Text] [Related]
8. The P16/cyclin D1/Rb pathway in neuroendocrine tumors of the lung.
Beasley MB; Lantuejoul S; Abbondanzo S; Chu WS; Hasleton PS; Travis WD; Brambilla E
Hum Pathol; 2003 Feb; 34(2):136-42. PubMed ID: 12612881
[TBL] [Abstract][Full Text] [Related]
9. Molecular markers for reinforcement of histological subclassification of neuroendocrine lung tumors.
Kobayashi Y; Tokuchi Y; Hashimoto T; Hayashi M; Nishimura H; Ishikawa Y; Nakagawa K; Sato Y; Takahashi A; Tsuchiya E
Cancer Sci; 2004 Apr; 95(4):334-41. PubMed ID: 15072592
[TBL] [Abstract][Full Text] [Related]
10. High frequency and heterogeneous distribution of p53 mutations in aflatoxin B1-induced mouse lung tumors.
Tam AS; Foley JF; Devereux TR; Maronpot RR; Massey TE
Cancer Res; 1999 Aug; 59(15):3634-40. PubMed ID: 10446974
[TBL] [Abstract][Full Text] [Related]
11. Neuroendocrine neoplasms of the lung: a prognostic spectrum.
Asamura H; Kameya T; Matsuno Y; Noguchi M; Tada H; Ishikawa Y; Yokose T; Jiang SX; Inoue T; Nakagawa K; Tajima K; Nagai K
J Clin Oncol; 2006 Jan; 24(1):70-6. PubMed ID: 16382115
[TBL] [Abstract][Full Text] [Related]
12. Pulmonary atypical carcinoid: predictors of survival in 106 cases.
Beasley MB; Thunnissen FB; Brambilla E; Hasleton P; Steele R; Hammar SP; Colby TV; Sheppard M; Shimosato Y; Koss MN; Falk R; Travis WD
Hum Pathol; 2000 Oct; 31(10):1255-65. PubMed ID: 11070119
[TBL] [Abstract][Full Text] [Related]
13. Molecular markers help characterize neuroendocrine lung tumors.
Rusch VW; Klimstra DS; Venkatraman ES
Ann Thorac Surg; 1996 Sep; 62(3):798-809; discussion 809-10. PubMed ID: 8784011
[TBL] [Abstract][Full Text] [Related]
14. [Clinicopathological study on primary lung cancer--immunohistochemical expression of p53 suppressor gene and bcl-2 oncogene in relation to prognosis].
Irie K; Ishida H; Furukawa T; Koyanagi K; Miyamoto Y
Rinsho Byori; 1996 Jan; 44(1):32-41. PubMed ID: 8691638
[TBL] [Abstract][Full Text] [Related]
15. Abnormal p53 expression in lung neuroendocrine tumors. Diagnostic and prognostic implications.
Roncalli M; Doglioni C; Springall DR; Papotti M; Pagani A; Polak JM; Ibrahim NB; Coggi G; Viale G
Diagn Mol Pathol; 1992 Jun; 1(2):129-35. PubMed ID: 1364172
[TBL] [Abstract][Full Text] [Related]
16. Expression of L-type amino acid transporter 1 (LAT1) in neuroendocrine tumors of the lung.
Kaira K; Oriuchi N; Imai H; Shimizu K; Yanagitani N; Sunaga N; Hisada T; Kawashima O; Iijima H; Ishizuka T; Kanai Y; Endou H; Nakajima T; Mori M
Pathol Res Pract; 2008; 204(8):553-61. PubMed ID: 18440724
[TBL] [Abstract][Full Text] [Related]
17. Expression of Bcl-2 in lung neuroendocrine tumours: comparison with p53.
Wang DG; Johnston CF; Sloan JM; Buchanan KD
J Pathol; 1998 Mar; 184(3):247-51. PubMed ID: 9614375
[TBL] [Abstract][Full Text] [Related]
18. Pulmonary large cell neuroendocrine carcinoma demonstrates high proliferative activity.
Iyoda A; Hiroshima K; Moriya Y; Mizobuchi T; Otsuji M; Sekine Y; Shibuya K; Iizasa T; Saitoh Y; Fujisawa T
Ann Thorac Surg; 2004 Jun; 77(6):1891-5; discussion 1895. PubMed ID: 15172230
[TBL] [Abstract][Full Text] [Related]
19. Chromosomal aberrations in a series of large-cell neuroendocrine carcinomas: unexpected divergence from small-cell carcinoma of the lung.
Ullmann R; Petzmann S; Sharma A; Cagle PT; Popper HH
Hum Pathol; 2001 Oct; 32(10):1059-63. PubMed ID: 11679939
[TBL] [Abstract][Full Text] [Related]
20. Genetic alterations in early-stage pulmonary large cell neuroendocrine carcinoma.
Hiroshima K; Iyoda A; Shibuya K; Haga Y; Toyozaki T; Iizasa T; Nakayama T; Fujisawa T; Ohwada H
Cancer; 2004 Mar; 100(6):1190-8. PubMed ID: 15022286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]